These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 10872715)

  • 21. Evaluation of immune responses induced by HIV-1 gp120 in rhesus macaques: effect of vaccination on challenge with pathogenic strains of homologous and heterologous simian human immunodeficiency viruses.
    Kumar A; Lifson JD; Silverstein PS; Jia F; Sheffer D; Li Z; Narayan O
    Virology; 2000 Aug; 274(1):149-64. PubMed ID: 10936096
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunogenicity and effect of a virosomal influenza vaccine on viral replication and T-cell activation in HIV-infected children receiving highly active antiretroviral therapy.
    Tanzi E; Esposito S; Bojanin J; Amendola A; Trabattoni D; Pariani E; Pinzani R; Zanetti A; Principi N
    J Med Virol; 2006 Apr; 78(4):440-5. PubMed ID: 16482542
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influenza virus-specific cytotoxic T lymphocytes: a correlate of protection and a basis for vaccine development.
    Rimmelzwaan GF; Fouchier RA; Osterhaus AD
    Curr Opin Biotechnol; 2007 Dec; 18(6):529-36. PubMed ID: 18083548
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A one-size-fits-all flu vaccine?
    Kaiser J
    Science; 2006 Apr; 312(5772):380-2. PubMed ID: 16627732
    [No Abstract]   [Full Text] [Related]  

  • 25. Enhanced protective immunity against H5N1 influenza virus challenge by vaccination with DNA expressing a chimeric hemagglutinin in combination with an MHC class I-restricted epitope of nucleoprotein in mice.
    Tao P; Luo M; Pan R; Ling D; Zhou S; Tien P; Pan Z
    Antiviral Res; 2009 Mar; 81(3):253-60. PubMed ID: 19135483
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dendritic cell vaccination induces cross-reactive cytotoxic T lymphocytes specific for wild-type and natural variant human immunodeficiency virus type 1 epitopes in HLA-A*0201/Kb transgenic mice.
    Abdel-Motal UM; Friedline R; Poligone B; Pogue-Caley RR; Frelinger JA; Tisch R
    Clin Immunol; 2001 Oct; 101(1):51-8. PubMed ID: 11580226
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New assays to measure equine influenza virus-specific Type 1 immunity in horses.
    Paillot R; Kydd JH; MacRae S; Minke JM; Hannant D; Daly JM
    Vaccine; 2007 Oct; 25(42):7385-98. PubMed ID: 17881098
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers.
    Belshe RB; Stevens C; Gorse GJ; Buchbinder S; Weinhold K; Sheppard H; Stablein D; Self S; McNamara J; Frey S; Flores J; Excler JL; Klein M; Habib RE; Duliege AM; Harro C; Corey L; Keefer M; Mulligan M; Wright P; Celum C; Judson F; Mayer K; McKirnan D; Marmor M; Woody G;
    J Infect Dis; 2001 May; 183(9):1343-52. PubMed ID: 11294665
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel mechanism for HIV1-mediated bystander CD4+ T-cell death: neighboring dying cells drive the capacity of HIV1 to kill noncycling primary CD4+ T cells.
    Lelièvre JD; Mammano F; Arnoult D; Petit F; Grodet A; Estaquier J; Ameisen JC
    Cell Death Differ; 2004 Sep; 11(9):1017-27. PubMed ID: 15118766
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Why high levels of virus-specific CTL persist in HIV1-infected individuals.
    Koup RA; Sullivan JL
    Res Immunol; 1989 Jan; 140(1):92-5; discussion 118-9. PubMed ID: 2543042
    [No Abstract]   [Full Text] [Related]  

  • 31. Influenza vaccination and false positive HIV results.
    Erickson CP; McNiff T; Klausner JD
    N Engl J Med; 2006 Mar; 354(13):1422-3. PubMed ID: 16571889
    [No Abstract]   [Full Text] [Related]  

  • 32. HIV and AIDS.
    Laman JD
    Science; 1993 Jun; 260(5115):1707-8. PubMed ID: 8511573
    [No Abstract]   [Full Text] [Related]  

  • 33. Immune surveillance and AIDS progression.
    Zinkernagel R; Klenerman P
    Curr Biol; 1997 Jul; 7(7):R403-5. PubMed ID: 9210384
    [No Abstract]   [Full Text] [Related]  

  • 34. Vaccine outlooks. After negative publicity and a series of setbacks over HIV/AIDS and influenza, the prospects for research on new vaccines are improving.
    Hunter P
    EMBO Rep; 2010 Oct; 11(10):738-41. PubMed ID: 20877293
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HIV recent advances in AIDS research: genetics, molecular biology and immunology.
    Landau NR
    Curr Opin Immunol; 1999 Aug; 11(4):449-50. PubMed ID: 10448145
    [No Abstract]   [Full Text] [Related]  

  • 36. Smallpox and AIDS.
    Battershill JH
    CMAJ; 1994 Jan; 150(2):128. PubMed ID: 8287331
    [No Abstract]   [Full Text] [Related]  

  • 37. [Astra research on an antiviral agent against AIDS is offered gratis to those seriously interested].
    Rosell S
    Lakartidningen; 1988 Jun; 85(25):2278-9. PubMed ID: 3386357
    [No Abstract]   [Full Text] [Related]  

  • 38. The choice of antigen for therapeutic immunization against AIDS.
    van Baalen CA; Stittelaar KJ; Osterhaus AD; Guillon C; Gruters RA
    Trends Immunol; 2002 Oct; 23(10):478-9. PubMed ID: 12297418
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [HIV infection and vaccination].
    Iwarson S
    Lakartidningen; 1988 May; 85(19):1683-6. PubMed ID: 3374199
    [No Abstract]   [Full Text] [Related]  

  • 40. Understanding HIV1, cytokines and effective immunity: bridging the gap between cytokine regulation in vitro and in vivo.
    Montaner LJ
    Res Immunol; 1994; 145(8-9):575-7. PubMed ID: 7754202
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.